---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-049634"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2022-04-25T23:59:59+00:00"
generated_at: "2026-06-26T04:58:22.549275+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CVRx Q1 revenue $4.1M (+43% YoY); US HF revenue up 133% to $2.9M

## Summary
- Net loss $10.0M ($0.49 per share) vs $8.6M loss ($23.92 per share) in Q1 2021; weighted avg shares 20.45M.
- U.S. active implanting centers grew to 56 from 19; sales territories expanded to 17 from 6 year-over-year.
- Cash $131.2M at Mar 31, 2022; full-year 2022 revenue guidance $20-23M; Q2 expected $4.5-5M.
- Received FDA approval for new tablet-form factor programmer in April 2022.
- Gross margin improved to 77% from 70%; R&D $2.3M (+29%), SG&A $10.8M (+142%).

## SEC filing metadata
- accession: 0001104659-22-049634
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2022-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465922049634/0001104659-22-049634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465922049634/tm2213448d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-049634
- JSON: https://secwatch.observer/filing/0001104659-22-049634.json
- Plain text: https://secwatch.observer/filing/0001104659-22-049634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.